Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Organism | |
Product Type | Organoid |
Tissue | Colon |
Disease | Colorectal cancer |
Applications
Oncology
The oncology drug efficacy evaluation platform is based on patient-derived organoids(PDOs).
This platform allows for the assessment of the efficacy of oncology agents and immunotherapeutics by utilizing a co-culture system with immune cells from the tumor microenvironment.
Immuno-Oncology
This provides a solution for assessing the effectiveness of immunotherapeutic agents targeting cytotoxic T cells in co-culture with cancer organoids.
Tumor Microenvironment
CAFs promote cancer invasion and metastasis, potentially inducing resistance to anticancer drugs. Considering these functions of CAFs is crucial for accurately assessing the efficacy of anticancer drugs and developing strategies to address these challenges.
Cancer Vaccine
Lead the future of treatment with our innovative cancer vaccine and mRNA therapy platform! Discover advanced solutions that provide better health and hope through our cutting-edge technology and scientific approach
Our colorectal cancer organoids accurately replicate patient tumors by expressing key markers CDX2, β-catenin, and CK20, underscoring their fidelity for cancer research and personalized treatment development.
This molecular mimicry enables a profound understanding of colorectal cancer’s pathology and offers a promising avenue for therapeutic innovations.
Colorectal cancer organoid
H&E | CDX2 | β-catenin | CK20 | |
|---|---|---|---|---|
Cancer tissue |  |  |  |  |
Cancer organoid |  |  |  |  |
Cancer organoid |  |  |  |  |
Immunofluorescent staining with a proliferation marker (Ki-67), an epithelial marker (ECAD) and mature intestinal markers (DEFA5, OLFM4, MUC13, and KRT20).
Unlock the essence of precision in cancer treatment with our colorectal cancer organoids, mirroring the genetic markers of colorectal cancer.
Experience the future of testing you drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing.
Dive into a new era of oncology, where your individuality guides our innovation.
Oncoplot of the top 26 most frequently mutated genes in 22 cases.
Exploring genetic links in colorectal cancer crganoids: We analyze genetic correlations using a database of mutant proteins and their interactions to uncover critical insights into colorectal cancer.
Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses.
Transform the standard with us—where your medication’s potential is as unique as you are.
Tissue
Normal |  |  |  |  |  |
Cancer |  |  |  |  |  |
BAT25 MSI (+) LOH: Uninformative | BAT26 MSI (+) LOH: Uninformative | D2S123 MSI (-) LOH: (-) | D5S346 MSI (+) LOH: (-) | D17S250 MSI (+) LOH: (-) |
Organoid
Normal |  |  |  |  |  |
Cancer |  |  |  |  |  |
BAT25 MSI (+) LOH: Uninformative | BAT26 MSI (+) LOH: Uninformative | D2S123 MSI (-) LOH: (-) | D5S346 MSI (+) LOH: (+) L=0.312 | D17S250 MSI (+) LOH: (-) |
Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses. Transform the standard with us—where your medication’s potential is as unique as you are.
5-FU |  |  |  |  |  |  |
Ctr | 0.04μM | 0.48μM | 7.8μM | 125μM | 500μM | |
Oxaliplatin |  |  |  |  |  |  |
Ctr | 0.12μM | 0.32μM | 0.8μM | 20μM | 100μM | |
Irinotecan |  |  |  |  |  |  |
Ctr | 0.12μM | 0.32μM | 0.8μM | 20μM | 100μM |
Oxaliplatin
Irinotecan
5-FU
Drug responses of patient-derived colorectal cancer organoids.
Dose-response curves generated from patient-derived colorectal cancer organoid lines treated with oxaliplatin, Irinotecan and 5-FU.
These figures demonstrate the percent of cell viability measured.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
